Literature DB >> 11389157

The -48 C/T polymorphism in the presenilin 1 promoter is associated with an increased risk of developing Alzheimer's disease and an increased Abeta load in brain.

J C Lambert1, D M Mann, J M Harris, M C Chartier-Harlin, A Cumming, J Coates, H Lemmon, D StClair, T Iwatsubo, C Lendon.   

Abstract

Mutations in the presenilin 1 gene (PS1) account for the majority of early onset, familial, autosomal dominant forms of Alzheimer's disease (AD), whereas its role in other late onset forms of AD remains unclear. A -48 C/T polymorphism in the PS1 promoter has been associated with an increased genetic risk in early onset complex AD and moreover has been shown to influence the expression of the PS1 gene. This raises the possibility that previous conflicting findings from association studies with homozygosity for the PS1 intron 8 polymorphism might be the result of linkage disequilibrium with the -48 CC genotype. Here we provide further evidence of increased risk of AD associated with homozygosity for the -48 CC genotype (odds ratio=1.6). We also report a phenotypic correlation with Abeta(40), Abeta(42(43)), and total Abeta load in AD brains. The -48 CC genotype was associated with 47% greater total Abeta load (p<0.003) compared to CT + TT genotype bearers. These results suggest that the -48 C/T polymorphism in the PS1 promoter may increase the risk of AD, perhaps by altering PS1 gene expression and thereby influencing Abeta load.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11389157      PMCID: PMC1734889          DOI: 10.1136/jmg.38.6.353

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  19 in total

Review 1.  Amyloid, the presenilins and Alzheimer's disease.

Authors:  J Hardy
Journal:  Trends Neurosci       Date:  1997-04       Impact factor: 13.837

2.  Genetic association of the presenilin-1 regulatory region with early-onset Alzheimer's disease in a population-based sample.

Authors:  C M van Duijn; M Cruts; J Theuns; G Van Gassen; H Backhovens; M van den Broeck; A Wehnert; S Serneels; A Hofman; C Van Broeckhoven
Journal:  Eur J Hum Genet       Date:  1999 Oct-Nov       Impact factor: 4.246

3.  Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43).

Authors:  T Iwatsubo; A Odaka; N Suzuki; H Mizusawa; N Nukina; Y Ihara
Journal:  Neuron       Date:  1994-07       Impact factor: 17.173

Review 4.  Exploring the etiology of Alzheimer disease using molecular genetics.

Authors:  C L Lendon; F Ashall; A M Goate
Journal:  JAMA       Date:  1997-03-12       Impact factor: 56.272

Review 5.  Transcriptional regulation of Alzheimer's disease genes: implications for susceptibility.

Authors:  J Theuns; C Van Broeckhoven
Journal:  Hum Mol Genet       Date:  2000-10       Impact factor: 6.150

6.  An intronic polymorphism in the presenilin-1 gene does not influence the amount or molecular form of the amyloid beta protein deposited in Alzheimer's disease.

Authors:  D M Mann; S M Pickering-Brown; N N Bayatti; A E Wright; F Owen; T Iwatsubo; T C Saido
Journal:  Neurosci Lett       Date:  1997-01-24       Impact factor: 3.046

7.  Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1.

Authors:  Y M Li; M Xu; M T Lai; Q Huang; J L Castro; J DiMuzio-Mower; T Harrison; C Lellis; A Nadin; J G Neduvelil; R B Register; M K Sardana; M S Shearman; A L Smith; X P Shi; K C Yin; J A Shafer; S J Gardell
Journal:  Nature       Date:  2000-06-08       Impact factor: 49.962

8.  The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology.

Authors:  C A Lemere; F Lopera; K S Kosik; C L Lendon; J Ossa; T C Saido; H Yamaguchi; A Ruiz; A Martinez; L Madrigal; L Hincapie; J C Arango; D C Anthony; E H Koo; A M Goate; D J Selkoe; J C Arango
Journal:  Nat Med       Date:  1996-10       Impact factor: 53.440

9.  Genetic association between intronic polymorphism in presenilin-1 gene and late-onset Alzheimer's disease. Alzheimer's Disease Collaborative Group.

Authors:  M Wragg; M Hutton; C Talbot
Journal:  Lancet       Date:  1996-02-24       Impact factor: 79.321

10.  Genetic variability at the amyloid-beta precursor protein locus may contribute to the risk of late-onset Alzheimer's disease.

Authors:  F Wavrant-De Vrièze; R Crook; P Holmans; P Kehoe; M J Owen; J Williams; K Roehl; D K Lahiri; S Shears; J Booth; W Wu; A Goate; M C Chartier-Harlin; J Hardy; J Pérez-Tur
Journal:  Neurosci Lett       Date:  1999-07-09       Impact factor: 3.046

View more
  16 in total

1.  Long-term high-dose atorvastatin decreases brain oxidative and nitrosative stress in a preclinical model of Alzheimer disease: a novel mechanism of action.

Authors:  Eugenio Barone; Giovanna Cenini; Fabio Di Domenico; Sarah Martin; Rukhsana Sultana; Cesare Mancuso; Michael Paul Murphy; Elizabeth Head; D Allan Butterfield
Journal:  Pharmacol Res       Date:  2010-12-27       Impact factor: 7.658

Review 2.  Redox proteomics and amyloid β-peptide: insights into Alzheimer disease.

Authors:  D Allan Butterfield; Debra Boyd-Kimball
Journal:  J Neurochem       Date:  2018-11-27       Impact factor: 5.372

3.  The gene encoding nicastrin, a major gamma-secretase component, modifies risk for familial early-onset Alzheimer disease in a Dutch population-based sample.

Authors:  Bart Dermaut; Jessie Theuns; Kristel Sleegers; Hiroshi Hasegawa; Marleen Van den Broeck; Krist'l Vennekens; Ellen Corsmit; Peter St George-Hyslop; Marc Cruts; Cornelia M van Duijn; Christine Van Broeckhoven
Journal:  Am J Hum Genet       Date:  2002-04-24       Impact factor: 11.025

Review 4.  Alzheimer's Disease and Frontotemporal Dementia: The Current State of Genetics and Genetic Testing Since the Advent of Next-Generation Sequencing.

Authors:  Jill S Goldman; Vivianna M Van Deerlin
Journal:  Mol Diagn Ther       Date:  2018-10       Impact factor: 4.074

5.  Decreased levels of PSD95 and two associated proteins and increased levels of BCl2 and caspase 3 in hippocampus from subjects with amnestic mild cognitive impairment: Insights into their potential roles for loss of synapses and memory, accumulation of Abeta, and neurodegeneration in a prodromal stage of Alzheimer's disease.

Authors:  Rukhsana Sultana; William A Banks; D Allan Butterfield
Journal:  J Neurosci Res       Date:  2010-02-15       Impact factor: 4.164

Review 6.  Oxidatively modified, mitochondria-relevant brain proteins in subjects with Alzheimer disease and mild cognitive impairment.

Authors:  Rukhsana Sultana; D Allan Butterfield
Journal:  J Bioenerg Biomembr       Date:  2009-10       Impact factor: 2.945

Review 7.  Current status on Alzheimer disease molecular genetics: from past, to present, to future.

Authors:  Karolien Bettens; Kristel Sleegers; Christine Van Broeckhoven
Journal:  Hum Mol Genet       Date:  2010-04-13       Impact factor: 6.150

Review 8.  Oxidatively modified proteins in Alzheimer's disease (AD), mild cognitive impairment and animal models of AD: role of Abeta in pathogenesis.

Authors:  Rukhsana Sultana; Marzia Perluigi; D Allan Butterfield
Journal:  Acta Neuropathol       Date:  2009-03-14       Impact factor: 17.088

Review 9.  Sequence analyses of presenilin mutations linked to familial Alzheimer's disease.

Authors:  Sun Don Kim; Jinoh Kim
Journal:  Cell Stress Chaperones       Date:  2008-05-20       Impact factor: 3.667

Review 10.  Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment.

Authors:  D Allan Butterfield; Tanea Reed; Shelley F Newman; Rukhsana Sultana
Journal:  Free Radic Biol Med       Date:  2007-06-13       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.